PET scan to track immunotherapy response in advanced sarcoma
Part of Cancer clinical trials.
This trial uses a special PET scan called 68Ga-grazytracer to see how well your soft tissue sarcoma responds to immunotherapy treatment. It may help doctors understand if the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of a type of soft tissue sarcoma (such as fibrosarcoma, liposarcoma, or others listed).
- Your doctor plans to treat you with immunotherapy or a combination that includes immunotherapy.
- You are between 6 and 80 years old.
- You do not have severe health problems like serious heart, lung, bone marrow, liver, or kidney disease.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan called 68Ga-grazytracer to see how well immunotherapy is working in people with stomach, colon, or other gastrointestinal cancers. The goal is to find out if this scan can help doctors track your response to treatment.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working for pancreatic cancer. It may help your doctor understand if your treatment is effective.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial uses a special PET scan to see how well your breast cancer is responding to neoadjuvant therapy (treatment given before surgery). The goal is to help doctors personalize your care by checking if the cancer is shrinking.
Hear when a new Advanced Soft Tissue Sarcomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.